CN104220062B - (3s,3s’)4,4’-二硫烷二基双(3-氨基丁烷1-磺酸)和第二抗高血压药的组合 - Google Patents

(3s,3s’)4,4’-二硫烷二基双(3-氨基丁烷1-磺酸)和第二抗高血压药的组合 Download PDF

Info

Publication number
CN104220062B
CN104220062B CN201280069935.4A CN201280069935A CN104220062B CN 104220062 B CN104220062 B CN 104220062B CN 201280069935 A CN201280069935 A CN 201280069935A CN 104220062 B CN104220062 B CN 104220062B
Authority
CN
China
Prior art keywords
combination
sulfonic acid
enalapril
oral
active constituent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280069935.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN104220062A (zh
Inventor
凯瑟琳·洛朗-科特斯
亚尼·马克
吉·高-德利昂
法布里斯·巴拉瓦纳
莱昂内尔·塞加尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Quantum Genomics SA
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Quantum Genomics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Quantum Genomics SA filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to CN201810509836.2A priority Critical patent/CN109464432A/zh
Publication of CN104220062A publication Critical patent/CN104220062A/zh
Application granted granted Critical
Publication of CN104220062B publication Critical patent/CN104220062B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201280069935.4A 2011-12-21 2012-12-21 (3s,3s’)4,4’-二硫烷二基双(3-氨基丁烷1-磺酸)和第二抗高血压药的组合 Expired - Fee Related CN104220062B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810509836.2A CN109464432A (zh) 2011-12-21 2012-12-21 (3s,3s’)4,4’-二硫烷二基双(3-氨基丁烷1-磺酸)和第二抗高血压药的组合

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11306735 2011-12-21
EP11306735.9 2011-12-21
PCT/EP2012/076607 WO2013092984A1 (en) 2011-12-21 2012-12-21 Combination of (3s,3s') 4,4'-disulfanediylbis(3-aminobutane 1-sulfonic acid) and a second antihypertensive agent

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201810509836.2A Division CN109464432A (zh) 2011-12-21 2012-12-21 (3s,3s’)4,4’-二硫烷二基双(3-氨基丁烷1-磺酸)和第二抗高血压药的组合

Publications (2)

Publication Number Publication Date
CN104220062A CN104220062A (zh) 2014-12-17
CN104220062B true CN104220062B (zh) 2018-06-15

Family

ID=47522577

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280069935.4A Expired - Fee Related CN104220062B (zh) 2011-12-21 2012-12-21 (3s,3s’)4,4’-二硫烷二基双(3-氨基丁烷1-磺酸)和第二抗高血压药的组合
CN201810509836.2A Pending CN109464432A (zh) 2011-12-21 2012-12-21 (3s,3s’)4,4’-二硫烷二基双(3-氨基丁烷1-磺酸)和第二抗高血压药的组合

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201810509836.2A Pending CN109464432A (zh) 2011-12-21 2012-12-21 (3s,3s’)4,4’-二硫烷二基双(3-氨基丁烷1-磺酸)和第二抗高血压药的组合

Country Status (25)

Country Link
US (1) US10959938B2 (https=)
EP (1) EP2793878B1 (https=)
JP (2) JP6212500B2 (https=)
KR (1) KR20140116879A (https=)
CN (2) CN104220062B (https=)
AU (1) AU2012356895B2 (https=)
BR (1) BR112014015276B1 (https=)
CA (1) CA2859704C (https=)
CY (1) CY1118711T1 (https=)
DK (1) DK2793878T3 (https=)
EA (1) EA028718B1 (https=)
ES (1) ES2619027T3 (https=)
HR (1) HRP20170267T1 (https=)
HU (1) HUE033403T2 (https=)
IL (1) IL233156B (https=)
IN (1) IN2014DN05787A (https=)
LT (1) LT2793878T (https=)
MX (1) MX345469B (https=)
PL (1) PL2793878T3 (https=)
PT (1) PT2793878T (https=)
RS (1) RS55774B1 (https=)
SI (1) SI2793878T1 (https=)
SM (1) SMT201700156T1 (https=)
WO (1) WO2013092984A1 (https=)
ZA (1) ZA201405266B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014015276B1 (pt) * 2011-12-21 2020-09-29 Quantum Genomics Combinação de (3s,3s) 4,4-dissulfanodiilbis(ácido 3-aminobutano 1-sulfônico) e um segundo agente anti-hipertensivo
TW202207917A (zh) * 2020-05-06 2022-03-01 法商量子基因科技有限公司 包含腦胺肽酶抑制劑、利尿劑及全身性腎素－血管收縮素系統阻斷劑之醫藥組合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060135602A1 (en) * 2002-07-16 2006-06-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Novel derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulfphonates) and compositions containing same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2773712B1 (fr) 1998-01-16 2000-06-02 Inst Nat Sante Rech Med Composition pharmaceutique comprenant au moins un inhibiteur de l'aminopeptidase a
FR2858617A1 (fr) * 2003-08-06 2005-02-11 Inst Nat Sante Rech Med Derives de 4',4'-dithiobis-(3-aminobutane-1-sulfonate-1- sulfonates) nouveaux et compositions les contenant
US20080014187A1 (en) * 2006-07-15 2008-01-17 Bryant Villeponteau Compositions and Methods for Treating Hypertension and Inflammation
BR112014015276B1 (pt) * 2011-12-21 2020-09-29 Quantum Genomics Combinação de (3s,3s) 4,4-dissulfanodiilbis(ácido 3-aminobutano 1-sulfônico) e um segundo agente anti-hipertensivo

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060135602A1 (en) * 2002-07-16 2006-06-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Novel derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulfphonates) and compositions containing same

Also Published As

Publication number Publication date
MX2014007547A (es) 2014-08-01
CA2859704A1 (en) 2013-06-27
NZ627251A (en) 2015-08-28
IL233156B (en) 2018-05-31
US20150320703A1 (en) 2015-11-12
US10959938B2 (en) 2021-03-30
JP6726138B2 (ja) 2020-07-22
JP6212500B2 (ja) 2017-10-11
HRP20170267T1 (hr) 2017-05-19
JP2015506338A (ja) 2015-03-02
BR112014015276A2 (pt) 2017-06-13
JP2017222696A (ja) 2017-12-21
PT2793878T (pt) 2017-03-23
MX345469B (es) 2017-02-01
WO2013092984A1 (en) 2013-06-27
PL2793878T3 (pl) 2017-08-31
ZA201405266B (en) 2016-06-29
SI2793878T1 (sl) 2017-07-31
CN109464432A (zh) 2019-03-15
SMT201700156T1 (it) 2017-05-08
IL233156A0 (en) 2014-07-31
HUE033403T2 (en) 2017-11-28
HK1203051A1 (en) 2015-10-16
DK2793878T3 (en) 2017-03-27
LT2793878T (lt) 2017-05-25
EP2793878B1 (en) 2017-02-01
EP2793878A1 (en) 2014-10-29
ES2619027T3 (es) 2017-06-22
AU2012356895B2 (en) 2017-05-25
IN2014DN05787A (https=) 2015-05-15
CN104220062A (zh) 2014-12-17
KR20140116879A (ko) 2014-10-06
BR112014015276A8 (pt) 2017-06-13
BR112014015276B1 (pt) 2020-09-29
CY1118711T1 (el) 2017-07-12
EA201400724A1 (ru) 2014-09-30
RS55774B1 (sr) 2017-07-31
CA2859704C (en) 2020-04-28
EA028718B1 (ru) 2017-12-29
AU2012356895A1 (en) 2014-07-31

Similar Documents

Publication Publication Date Title
TW200306799A (en) Combination of organic compounds
TW201332547A (zh) 用於預防或治療貓之全身性疾病之血管緊張素ｉｉ受體拮抗劑
CN113876768B (zh) 一种阿利沙坦酯氨氯地平复方药物组合物的新应用
CN104220062B (zh) (3s,3s’)4,4’-二硫烷二基双(3-氨基丁烷1-磺酸)和第二抗高血压药的组合
JP2002535367A5 (https=)
JPH11507012A (ja) 心臓血管系病気の処置におけるアンギオテンシン変換酵素阻害薬と副作用軽減量のアルドステロン拮抗薬との組合わせ治療
AU2013247291A1 (en) Lercanidipine hydrochloride and losartan potassium compound preparation and preparation method thereof
RU2539382C2 (ru) Лекарственное средство для лечения гипертензии или повышенного кровяного давления
NZ627251B2 (en) Combination of (3s,3s') 4,4'-disulfanediylbis(3-aminobutane 1-sulfonic acid) and a second antihypertensive agent
HK1203051B (en) Combination of (3s,3s') 4,4'-disulfanediylbis(3-aminobutane 1-sulfonic acid) and a second antihypertensive agent
US20230233492A1 (en) Pharmaceutical combination comprising a brain aminopeptidase a inhibitor, a diuretic and a blocker of the systemic renin-angiotensin system
WO2011027021A1 (en) A method for the treatment of hypertension
JPH10513472A (ja) 心臓血管疾患の治療を目的とするアンギオテンシン変換酵素抑制物質、副作用軽減量のアルドステロン拮抗物質および利尿剤のコンビネーション療法
CN115737638A (zh) 一种阿利沙坦酯吲达帕胺复方药物组合物的新应用
IT201900006624A1 (it) Combinazione di canrenone e enalapril per uso nella terapia dei pazienti diabetici.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180615

CF01 Termination of patent right due to non-payment of annual fee